CD34 and acute myeloid leukemia: Furthermore, for ALX4, the antiproliferative effect was stronger for CD34+ than for CD34− AML cell populations (Figure 2b; p = 0.019), and for AML cells with no/minor morphological signs of differentiation (Figure 2c; FAB-M0/1 versus all others, p = 0.003).